Q&A with Safkhet's Fahmi Quadir: 'I love investigating frauds and making money at their expense'' - Financial News
The 'Short' Who Sank Valeant Stock - WSJ
Netflix Dirty Money — An Interview With Erin Lee Carr
Citron Research Report Is Out
The Valeant saga: Why the world needs short sellers
Valeant: Yes, Ackman's a Loser. But How Much Did Short Sellers Make? | Barron's
Hacked Printers. Fake Emails. Questionable Friends. Fahmi Quadir Was Up 24% Last Year, But It Came at a Price. | Institutional Investor
5 Most Successful Short Sellers of All Time - Insider Monkey
Safkhet Capital's Quadir Is Still Short Valeant - YouTube
Meet the short seller who rocked Valeant's stock this week - MarketWatch
Fahmi Quadir: A Short Seller named Assassin | LGT
Top investor Sequoia Fund sells Valeant stake | wkyc.com
Valeant Short Seller Dials Back Warning of Bombshell Report on Monday - WSJ
File:Valeant Pharmaceuticals' Business Model (26683524705) (cropped).jpg - Wikimedia Commons
What the Average Short Position in Valeant
Solved A Dirty Money: Drug Short (Netflix) or | Chegg.com
Valeant 'short' smells smoke — even when there's no fire
Netflix's 'Dirty Money' Exposes the Corporate Corruption Running the World | GQ
Watch Safkhet Capital's Quadir Is Still Short Valeant - Bloomberg
The Valeant Meltdown and Wall Street's Major Drug Problem | Vanity Fair
Short Sellers Don't Exist to Fix the Problems. They Exist to Shed Light on the Problems” - ProMarket
Valeant scandal shows why we need short-sellers in the stock market - Los Angeles Times
The Anti-Ackman: Valeant Short Sellers Have Made $2.8 Billion - Bloomberg
Solved NAME Module 3 - 10 points Dirty Money: Drug Short | Chegg.com
